KAM
IMGN

Kazazian Asset Management’s Immunogen Inc IMGN Stock Holding History

Kazazian Asset Management’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-46,644
Closed -$357K – 86
2017
Q3 		$357K Buy
+46,644
New +$310K 0.44% 50

Other funds holding IMGN

ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Kazazian Asset Management's IMGN Position: Q4 2017 in Review

Kazazian Asset Management sold out of Immunogen Inc (IMGN) in Q4 2017, closing a stake of 46,644 shares — an estimated $357K sold.

Kazazian Asset Management first reported a position in IMGN in Q3 2017 and held it in 1 quarter. The position peaked at $357K in Q3 2017. 200 funds tracked by Wall St. Rank hold IMGN as of Q4 2017.

  • Kazazian Asset Management reported no remaining Immunogen Inc position as of Q4 2017 after selling out during the quarter.
  • Kazazian Asset Management sold 46,644 Immunogen Inc shares in Q4 2017, an estimated $357K.
  • Kazazian Asset Management first reported a position in Immunogen Inc in Q3 2017 and held it in 1 quarter.
  • Kazazian Asset Management's Immunogen Inc position peaked at $357K in Q3 2017.
  • 200 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2017.

Based on Kazazian Asset Management's 13F filing for Q4 2017, filed 15 Feb 2018.